Angle signs AstraZeneca deal to develop prostate cancer assay
The assay development phase is expected to complete by early 2025.
06 May 2024
06 May 2024
The assay development phase is expected to complete by early 2025.
The Novostim 2 device uses transcranial random noise stimulation (tRNS), a non-invasive electrical stimulation, to abate symptoms of ADHD.
The FDA granted de novo classification to the Symani Surgical System for soft tissue manipulation in microsurgery in April 2024.
AI-driven cyberattacks are changing the cybersecurity needs of businesses, with the majority facing increasing talent shortages.
Telehealth has greatly increased patient engagement during the pandemic while AI and remote patient monitoring can increase the chances of detecting diseases or conditions early with real-time monitoring.
Karius will use the proceeds to expand access to its genomic diagnostics for infectious diseases.
The AI-driven ultrasound tool is designed to expedite diagnoses by cutting out the need for an ultrasound expert.
Lantheus will provide microbubbles and activation devices while SonoVascular will handle clinical study execution.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.